Equillium (NYSE:EQ) Posts Earnings Results, Beats Estimates By $0.04 EPS

Share on StockTwits

Equillium (NYSE:EQ) issued its quarterly earnings results on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04, Bloomberg Earnings reports.

Shares of Equillium stock opened at $3.76 on Wednesday. Equillium has a 52-week low of $3.10 and a 52-week high of $19.69. The business’s 50-day moving average price is $4.98.

A number of brokerages have recently issued reports on EQ. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Equillium in a research note on Tuesday. Zacks Investment Research upgraded shares of Equillium from a “sell” rating to a “hold” rating in a research note on Monday, July 15th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Equillium has an average rating of “Buy” and an average target price of $17.75.

Equillium Company Profile

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Further Reading: How to read a candlestick chart

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gamco Investors INC. ET AL Sells 1,500 Shares of Avid Technology, Inc.
Gamco Investors INC. ET AL Sells 1,500 Shares of Avid Technology, Inc.
Chicago Equity Partners LLC Increases Stock Position in Valhi, Inc.
Chicago Equity Partners LLC Increases Stock Position in Valhi, Inc.
Enviva Partners  Downgraded by Zacks Investment Research
Enviva Partners Downgraded by Zacks Investment Research
Evofem Biosciences  Downgraded to Hold at Zacks Investment Research
Evofem Biosciences Downgraded to Hold at Zacks Investment Research
First Bancorp  Cut to “Hold” at Zacks Investment Research
First Bancorp Cut to “Hold” at Zacks Investment Research
Four Corners Property Trust  Downgraded to “Sell” at Zacks Investment Research
Four Corners Property Trust Downgraded to “Sell” at Zacks Investment Research


© 2006-2019 Ticker Report